Cargando…

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling

BACKGROUND: Ovarian cancer (OC) ascites consist in a proinflammatory tumor environment that is characterized by the presence of various cytokines, chemokines and growth factors. The presence of these inflammatory-related factors in ascites is associated with a more aggressive tumor phenotype. CCL18...

Descripción completa

Detalles Bibliográficos
Autores principales: Lane, Denis, Matte, Isabelle, Laplante, Claude, Garde-Granger, Perrine, Carignan, Alex, Bessette, Paul, Rancourt, Claudine, Piché, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017134/
https://www.ncbi.nlm.nih.gov/pubmed/27613122
http://dx.doi.org/10.1186/s12943-016-0542-2
_version_ 1782452690820792320
author Lane, Denis
Matte, Isabelle
Laplante, Claude
Garde-Granger, Perrine
Carignan, Alex
Bessette, Paul
Rancourt, Claudine
Piché, Alain
author_facet Lane, Denis
Matte, Isabelle
Laplante, Claude
Garde-Granger, Perrine
Carignan, Alex
Bessette, Paul
Rancourt, Claudine
Piché, Alain
author_sort Lane, Denis
collection PubMed
description BACKGROUND: Ovarian cancer (OC) ascites consist in a proinflammatory tumor environment that is characterized by the presence of various cytokines, chemokines and growth factors. The presence of these inflammatory-related factors in ascites is associated with a more aggressive tumor phenotype. CCL18 is a member of CCL chemokines and its expression has been associated with poor prognosis in some cancers. However, its role in OC progression has not been established. Therefore, the aim of the current study was to elucidate the role of ascites CCL18 in OC progression. METHODS: ELISA and tissue microarrays were used to assess CCL18 in ascites and phospho-Pyk2 expression in cancer tissues respectively. Cell migration was assessed using Boyden chambers. CCL18 and ascites signaling was examined in ovarian cancer cells utilizing siRNA and exogenous gene expression. RESULTS: Here, we show that CCL18 levels are markedly increased in advanced serous OC ascites relative to peritoneal effusions from women with benign conditions. Ascites and CCL18 dose-dependently enhanced the migration of OC cell lines CaOV3 and OVCAR3. CCL18 levels in ascites positively correlated with the ability of ascites to promote cell migration. CCL18 blocking antibodies significantly attenuated ascites-induced cell migration. Ascites and CCL18 stimulated the phosphorylation of proline-rich tyrosine kinase 2 (Pyk2) in CaOV3 and OVCAR3 cells. Most importantly, the expression of phosphorylated Pyk2 in serous OC tumors was associated with shorter progression-free survival. Furthermore, enforced expression of Pyk2 promoted tumor cell migration while siRNA-mediated downregulation of Pyk2 attenuated cell migration. Downregulation of Pyk2 markedly inhibited ascites and CCL18-induced cell migration. CONCLUSIONS: Taken together, our findings establish an important role for CCL18, as a component of ascites, in the migration of tumor cells and identify Pyk2 as prognostic factor and a critical downstream signaling pathway for ascites-induced OC cell migration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-016-0542-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5017134
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50171342016-09-10 CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling Lane, Denis Matte, Isabelle Laplante, Claude Garde-Granger, Perrine Carignan, Alex Bessette, Paul Rancourt, Claudine Piché, Alain Mol Cancer Research BACKGROUND: Ovarian cancer (OC) ascites consist in a proinflammatory tumor environment that is characterized by the presence of various cytokines, chemokines and growth factors. The presence of these inflammatory-related factors in ascites is associated with a more aggressive tumor phenotype. CCL18 is a member of CCL chemokines and its expression has been associated with poor prognosis in some cancers. However, its role in OC progression has not been established. Therefore, the aim of the current study was to elucidate the role of ascites CCL18 in OC progression. METHODS: ELISA and tissue microarrays were used to assess CCL18 in ascites and phospho-Pyk2 expression in cancer tissues respectively. Cell migration was assessed using Boyden chambers. CCL18 and ascites signaling was examined in ovarian cancer cells utilizing siRNA and exogenous gene expression. RESULTS: Here, we show that CCL18 levels are markedly increased in advanced serous OC ascites relative to peritoneal effusions from women with benign conditions. Ascites and CCL18 dose-dependently enhanced the migration of OC cell lines CaOV3 and OVCAR3. CCL18 levels in ascites positively correlated with the ability of ascites to promote cell migration. CCL18 blocking antibodies significantly attenuated ascites-induced cell migration. Ascites and CCL18 stimulated the phosphorylation of proline-rich tyrosine kinase 2 (Pyk2) in CaOV3 and OVCAR3 cells. Most importantly, the expression of phosphorylated Pyk2 in serous OC tumors was associated with shorter progression-free survival. Furthermore, enforced expression of Pyk2 promoted tumor cell migration while siRNA-mediated downregulation of Pyk2 attenuated cell migration. Downregulation of Pyk2 markedly inhibited ascites and CCL18-induced cell migration. CONCLUSIONS: Taken together, our findings establish an important role for CCL18, as a component of ascites, in the migration of tumor cells and identify Pyk2 as prognostic factor and a critical downstream signaling pathway for ascites-induced OC cell migration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-016-0542-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-09-09 /pmc/articles/PMC5017134/ /pubmed/27613122 http://dx.doi.org/10.1186/s12943-016-0542-2 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lane, Denis
Matte, Isabelle
Laplante, Claude
Garde-Granger, Perrine
Carignan, Alex
Bessette, Paul
Rancourt, Claudine
Piché, Alain
CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling
title CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling
title_full CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling
title_fullStr CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling
title_full_unstemmed CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling
title_short CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling
title_sort ccl18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017134/
https://www.ncbi.nlm.nih.gov/pubmed/27613122
http://dx.doi.org/10.1186/s12943-016-0542-2
work_keys_str_mv AT lanedenis ccl18fromascitespromotesovariancancercellmigrationthroughprolinerichtyrosinekinase2signaling
AT matteisabelle ccl18fromascitespromotesovariancancercellmigrationthroughprolinerichtyrosinekinase2signaling
AT laplanteclaude ccl18fromascitespromotesovariancancercellmigrationthroughprolinerichtyrosinekinase2signaling
AT gardegrangerperrine ccl18fromascitespromotesovariancancercellmigrationthroughprolinerichtyrosinekinase2signaling
AT carignanalex ccl18fromascitespromotesovariancancercellmigrationthroughprolinerichtyrosinekinase2signaling
AT bessettepaul ccl18fromascitespromotesovariancancercellmigrationthroughprolinerichtyrosinekinase2signaling
AT rancourtclaudine ccl18fromascitespromotesovariancancercellmigrationthroughprolinerichtyrosinekinase2signaling
AT pichealain ccl18fromascitespromotesovariancancercellmigrationthroughprolinerichtyrosinekinase2signaling